New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:54 EDTPLXProtalix's agreement for UPLYSO with Brazil's Ministry of Health approved
Protalix BioTherapeutics announced that the Brazilian National Institute of Industrial Property has approved the company's previously-announced supply and technology transfer agreement with Fundação Oswaldo Cruz, an arm of the Brazilian Ministry of Health for UPLYSO (alfataliglicerase). The company has already completed the first shipment of the drug to Brazil under the agreement.
News For PLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2015
09:24 EDTPLXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Aoxing Pharmaceutical (AXN), up 15.5%. ALSO HIGHER: Wausau Paper (WPP), up 38.4% after announcing that it will be acquired by SCA... Protalix (PLX), up 12% after selling its share in the collaboration agreement for Elelyso to Pfizer (PFE)... AB InBev (BUD), up 1.5% following an agreement in principle with SABMiller (SBMRY)... Molson Coors (TAP), up 9.3% following an agreement in principle between AB InBev and SABMiller... Twitter (TWTR), up 3% after disclosing that it will cut about 8% of workforce. DOWN AFTER EARNINGS: Johnson & Johnson (JNJ), down 1.9%... Del Frisco's (DFRG), down 5.1%. ALSO LOWER: Emerald Oil (EOX), down 20.3% after revolving credit line cut to $120M from $200M... HeartWare (HTWR), down 16% after announcing that it may not re-initiate enrollment in its MVAD clinical trial in November... JetBlue (JBLU), down 6% after reporting September traffic... Arch Coal (ACI), down 5.4% after being downgraded to Underweight from Neutral at JPMorgan.
07:33 EDTPLXProtalix sells share in collaboration for Elelyso, 6% stake to Pfizer for $46M
Subscribe for More Information
October 5, 2015
08:16 EDTPLXProtalix to explore NASH as indication for PRX 106 oral anti-TNF
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use